|Bid||19.26 x 0|
|Ask||19.28 x 0|
|Day's Range||18.57 - 21.58|
|52 Week Range||6.31 - 24.75|
|PE Ratio (TTM)||107.11|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.12|
Pot legalization is coming next month, and big cannabis producers like Canopy Growth Corp (TSX:WEED)(NYSE:CGC) will be affected in a big way. What does that mean for investors?
Shareholders Approve Name Change to SOL Investments Corp. TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) is pleased to announce the results of Scythian’s special meeting of shareholders on September 14, 2018 (“Special Meeting”).
LEAMINGTON, ON, Sept. 14, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that Dennis Staudt has resigned from the Company's Board of Directors (the "Board"). Mr. Staudt served as Lead Independent Director and Chair of the Audit Committee, and he had been a member of the Board since 2014, before the company was publicly traded.
Down as much as 16% in the last week, Canopy Growth Corp (TSX:WEED)(NYSE:WEED) and other marijuana stocks' bubbles may be bursting.
Aphria Inc. (TSX:APH) stock has bounced around over the past two weeks with two major news stories having a big impact.
While the lifting of US federal prohibition on cannabis as a recreational or even medicinal drug may ...
Canada in particular is the focus as of late with a number of Canadian cannabis stocks benefiting in a big way from new highs in the market. According to estimates by cannabis researchers at ArcView Market Research in partnership with BDS Analytics, the latest revenue projections for the U.S. medical cannabis industry in 2018 is $4.3 billion versus $6.7 billion for adult use. Last year, medical marijuana sales came in just under $6 billion while adult use grabbed $2.6 billion.
LEAMINGTON, ON, Sept. 12, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a wholesale supply agreement with Emblem Cannabis Corp., wholly owned subsidiary of Emblem Corp. and a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("Emblem") to supply 175,000 kg of high-quality cannabis over a five-year period starting May 2019 (the "Agreement") with a total of 25,000 kg deliverable for the balance of the first year. Under the terms of the Agreement, Aphria will receive a non-refundable deposit of $22.8 million, which is comprised of $12.8 million in cash, and 6,952,169 of common shares of Emblem. "Aphria's total annualized production capabilities are about to reach 255,000kg in early 2019, which means we are not only well positioned to meet all of our supply commitments across Canada and anticipated international demand, but also have the capacity to support the projected demand through our partners," said Gregg Battersby, Vice President of Commercial Strategy at Aphria.
Just over 40 days after Canada’s official cannabis legalization date on October 17, 2018, consumers ...
The legalization of cannabis is taking hold on a global scale and even CEO's like Tesla's (TSLA) Elon Musk appear to be taking a liking to new legislation. Investors are now looking to Canadian marijuana stocks as these have continued to reach new milestones over recent months. With the industry expecting continued to grow after Oct. 17, when weed will become legal across Canada for any purpose, a number of investors are looking to get a piece of the action.
Why fighting off black market demand for cannabis may not be as easy as it sounds for companies like Aphria Inc. (TSX:APH), Cronos Group Inc (TSX:CRON)(NASDAQ:CRON), and Tilray Inc. (NASDAQ:TLRY).
Licensed marijuana producer Aphria Inc. says it has exited the U.S. market for now by completing the sale of its remaining holdings in Liberty Health Sciences Inc. The Ontario-based company said it has signed an agreement with a group of buyers to sell 64.1 million shares in Liberty Health for $59.1 million. Aphria said it will re-enter the American market and become a significant player in the U.S. cannabis industry when its federal laws are changed.
LEAMINGTON, ON, Sept. 6, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a share purchase agreement with a group of buyers, each acting individually and not in concert, including a member of the Serruya family, and has completed the sale of 64,118,462 shares (the "Shares") in Liberty Health Sciences, Inc. ("Liberty"), representing 100% of the Company's outstanding investment in Liberty. As part of the transaction, Aphria retains an irrevocable option to repurchase the Shares or any replacement securities from the buyers for a period of up to five years, subject to the satisfaction of certain conditions as further described below.
Supreme Cannabis receives approval for additional 20,000 sq.ft. of flowering rooms at 7ACRES facility New flowering rooms expected to support an increase in annual production potential to 13,330kg TORONTO ...
Toronto, Ontario based Tidal Royalty Corp. (CSE: RLTY.U) (OTC Pink: TDRYF), a leading provider of royalty ...
Beverage giants seem to be circling Canadian marijuana companies like Aurora Cannabis Inc. (TSX:ACB). Is time to get in ahead of them?
NEW YORK, NY / ACCESSWIRE / August 31, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
Aphria Inc. (TSX:APH) stock has surged in late August but could still have room to run ahead of recreational legalization.